# US 9,750,685 B2 · Ophthalmic device having therapeutic agent delivery capability and method of forming same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,750,685 B2 - Document ID: US9750685B2 - Status: Granted - Kind: B2 - Application number: 14/958,097 - Filed: 2015-12-03 - Published: 2016-03-24 - Granted: 2017-09-05 - Earliest claimed: 2008-07-21 - Assignees: Novartis AG - Applicants: Novartis AG - Inventors: Brett E. Thomes; Stephen J. Van Noy; Chi-Chun Tsai - Web page: https://patentgrep.com/patent/US9750685B2 ## CPC - A61K 9/0051: {Ocular inserts or implants} - A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide - A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems - A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} - A61P 27/02: Ophthalmic agents - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention is directed to ophthalmic devices that are loaded with therapeutic agent. The devices provide prolonged release of the therapeutic agent to the eye. The ophthalmic devices are typically formed of an ophthalmic material that is particularly desirable for the loading of therapeutic agent and/or the therapeutic agent is typically particularly desirable for loading to the ophthalmic material. ## Claims ### Claim 1 An ophthalmic device, comprising; a mass of material, the mass of material being an acrylic material, the mass of material including at least 70% by weight hydrophobic acrylate and the hydrophobic acrylate being formed of at least 90% by weight of one or more monomers selected from the group consisting of 2-phenyl ethyl acrylate (PEA) and 2-phenyl ethyl methacrylate (PEMA); and therapeutic agent disposed upon a peripheral surface of the mass of material wherein the therapeutic agent is hydrophobic and has a PC Log P that is at least 1.6 and wherein the therapeutic agent is an anti-infective agent; wherein the mass of material is configured for insertion into an eye of a human and wherein attraction of the therapeutic agent to the hydrophobic acrylate controls sustained release of the therapeutic agent such that less than 50% by weight of the therapeutic agent is released from the mass of material in a period that is at least one week when the mass is submerged in basic salt solution and wherein the mass of material, the device and the therapeutic agent are free of any amino acid. ### Claim 2 (depends on 1) An ophthalmic device as in claim 1 wherein the therapeutic agent has a PC Log P that is at least 2.0. ### Claim 3 (depends on 1) An ophthalmic device as in claim 1 wherein the hydrophobic acrylate is entirely 2-phenyl ethyl methacrylate. ### Claim 4 (depends on 1) An ophthalmic device as in claim 1 wherein the acrylic material includes a substantial portion of hydrophilic acrylate. ### Claim 5 (depends on 4) An ophthalmic device as in claim 4 wherein the hydrophilic acrylate includes 2-hydroxyethylmethacrylate. ### Claim 6 (depends on 4) An ophthalmic device as in claim 4 wherein the mass of material releases a controlled amount of therapeutic agent when submerged in basic salt solution and wherein the hydrophobic acrylate and the hydrophilic acrylate are present in the mass of material in amounts such that the controlled amount of therapeutic agent is less than 60% of the total therapeutic agent in a time period that is at least 5 days. ### Claim 7 (depends on 4) An ophthalmic device as in claim 4 wherein the amount of hydrophilic acrylate and hydrophobic acrylate are selected to provide a predetermined release profile for the therapeutic agent. ### Claim 8 (depends on 1) An ophthalmic device as in claim 1 wherein the therapeutic agent is a quinolone or aminoglycoside. ### Claim 9 (depends on 8) An ophthalmic device as in claim 8 wherein the therapeutic agent is ciprofloxacin, moxifloxacin, or gatifloxacin. ### Claim 10 (depends on 1) An ophthalmic device as in claim 1 wherein the mass of material is an intraocular lens selected from an Aphakic intraocular lens, an anterior Phakic intraocular lens and a posterior chamber Phakic intraocular lens. ### Claim 11 (depends on 1) An ophthalmic device as in claim 1 wherein the mass of material is a haptic of an intraocular lens. ### Claim 12 (depends on 1) An ophthalmic device as in claim 1 wherein the mass of material is located at least partially within an eye of an individual. ### Claim 13 (depends on 1) An ophthalmic device as in claim 1 wherein the mass of material is configured as part or the whole of an intraocular lens, a haptic of an intraocular lens or a separate piece that is inserted in the eye with or without an intraocular lens. ### Claim 14 (depends on 1) An ophthalmic device as in claim 1 wherein the mass of material releases a controlled amount of therapeutic agent when submerged in basic salt solution. ### Claim 15 (depends on 14) An ophthalmic device as in claim 14 wherein less than 50% by weight of the therapeutic agent is released from the ophthalmic device in the basic salt solution over a period that is at least one week. ### Claim 16 (depends on 1) An ophthalmic device as in claim 1 wherein the therapeutic agent has a PC Log P that is at least 1.6 and wherein the attraction of the therapeutic agent to the hydrophobic acrylate provides for sustained release of the therapeutic agent such that less than 50% by weight of the therapeutic agent is released from the mass of material in a period that is at least one week. ### Claim 17 (depends on 16) An ophthalmic device as in claim 16 wherein the hydrophobic acrylate is at least 70% by weight of the mass of material. ### Claim 18 An ophthalmic device consisting essentially of: a mass of material, the mass of material being formed of components that consist essentially of acrylic material, cross-linking agent, colored dye and UV absorbing material wherein the acrylic material includes at least 70% by weight hydrophobic acrylate and the hydrophobic acrylate being formed of at least 90% by weight of one or more monomers selected from the group consisting of 2-phenyl ethyl acrylate and 2-phenyl ethyl methacrylate; and therapeutic agent disposed upon a peripheral surface of the mass of material wherein the therapeutic agent is hydrophobic and has a PC Log P that is at least 1.0 and wherein the therapeutic agent consists of an ophthalmic drug that consists of an anti-infective agent; wherein the mass of material is configured for insertion into an eye of a human and wherein attraction of the therapeutic agent to the hydrophobic acrylate controls sustained release of the therapeutic agent such that less than 80% by weight of the therapeutic agent is released from the mass of material over a period that is at least three days when the mass is submerged in basic salt solution. ### Claim 19 (depends on 18) An ophthalmic device as in claim 18 wherein the therapeutic agent has a PC Log P that is at least 2.0. ### Claim 20 (depends on 18) An ophthalmic device as in claim 18 wherein the hydrophobic acrylate is entirely 2-phenyl ethyl methacrylate. ### Claim 21 (depends on 18) An ophthalmic device as in claim 18 wherein the mass of material is an intraocular lens selected from an Aphakic intraocular lens, an anterior Phakic intraocular lens and a posterior chamber Phakic intraocular lens. ### Claim 22 (depends on 18) An ophthalmic device as in claim 18 wherein the mass of material is a haptic of an intraocular lens. ### Claim 23 (depends on 18) An ophthalmic device as in claim 18 wherein the mass of material is located at least partially within an eye of an individual. ### Claim 24 (depends on 18) An ophthalmic device as in claim 18 wherein the therapeutic agent has a PC Log P that is at least 1.6 and wherein the attraction of the therapeutic agent to the hydrophobic acrylate provides for sustained release of the therapeutic agent such that less than 50% by weight of the therapeutic agent is released from the mass of material in a period that is at least one week.